Results 201 to 210 of about 31,786 (265)
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric +10 more
wiley +1 more source
Governing Evidence in Contentious Times: A GUARD Framework for Public Health Leadership. [PDF]
Chene G +4 more
europepmc +1 more source
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera +11 more
wiley +1 more source
Body composition indices align with thyroid variation in euthyroid Saudi adults: A cross-sectional study. [PDF]
Alrajhi DS +5 more
europepmc +1 more source
CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh +12 more
wiley +1 more source
Comparative Study of Elevated CA19-9 Levels in Non-Gastrointestinal Tumors Patients: Evaluation of Different Immunoassay Methods and Analysis of Potential Interfering Factors. [PDF]
Liu Y +5 more
europepmc +1 more source
Responsibility of an architect and punishment for an architect
openaire +2 more sources
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
The 'vulnerability code': Is cell identity the architect of its own decay? [PDF]
Bai D, Cao Z, Zhu C.
europepmc +1 more source

